246 related articles for article (PubMed ID: 25458369)
21. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment.
González-San Segundo C; Herranz-Amo F; Alvarez-González A; Cuesta-Álvaro P; Gómez-Espi M; Paños-Fagundo E; Santos-Miranda JA
Ann Surg Oncol; 2011 Oct; 18(10):2980-7. PubMed ID: 21431406
[TBL] [Abstract][Full Text] [Related]
23. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
24. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
25. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
26. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
27. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
28. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
29. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.
Martinez AA; Gonzalez JA; Chung AK; Kestin LL; Balasubramaniam M; Diokno AC; Ziaja EL; Brabbins DS; Vicini FA
Cancer; 2000 Jan; 88(2):425-32. PubMed ID: 10640977
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy.
de la Taille A; Flam TA; Thiounn N; Pontvert D; Saighi D; Zerbib M; Debré B
BJU Int; 2002 Dec; 90(9):887-92. PubMed ID: 12460351
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.
Catton C; Gospodarowicz M; Warde P; Panzarella T; Catton P; McLean M; Milosevic M
Radiother Oncol; 2001 Apr; 59(1):51-60. PubMed ID: 11295206
[TBL] [Abstract][Full Text] [Related]
33. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
[TBL] [Abstract][Full Text] [Related]
34. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients.
Peyromaure M; Allouch M; Eschwege F; Verpillat P; Debré B; Zerbib M
Urology; 2003 Sep; 62(3):503-7. PubMed ID: 12946755
[TBL] [Abstract][Full Text] [Related]
35. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis.
Wang Z; Ni Y; Chen J; Sun G; Zhang X; Zhao J; Zhu X; Zhang H; Zhu S; Dai J; Shen P; Zeng H
World J Surg Oncol; 2020 Feb; 18(1):42. PubMed ID: 32093688
[TBL] [Abstract][Full Text] [Related]
37. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
38. Margin details matter: The prognostic significance of pseudocapsule invasion at the site of involved margin in prostatectomy specimens.
Russo JK; Laszewski M; Rodacker M; Watkins PL; Dufan TA; Koleilat N; Watkins JM
Urol Oncol; 2015 Sep; 33(9):383.e1-7. PubMed ID: 26097050
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
40. Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.
Kim DS; Jeon SH; Chang SG; Lee SH
Korean J Urol; 2015 Oct; 56(10):703-9. PubMed ID: 26495071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
